The reduction in price target by a reputable analyst firm like Piper Sandler could lead to a negative short-term sentiment among investors, potentially causing a decrease in ASLAN Pharma's stock price. The Overweight rating suggests a positive long-term outlook, but the lowered price target indicates near-term challenges or adjustments in valuation expectations.